Table 3 Offer of on-site HCV testing services among Opioid Treatment Programs offering any HCV testing (either on-site or off-site)

Predictor variables

 Director race/ethnicity

1†

  African-American

2.76 (1.03, 7.35)*

  Other race/ethnicity

0.66 (0.19, 2.27)

  White

1†

 Director age

0.97 (0.94, 1.00)^

 Director gender

  Female

1.17 (0.65, 2.07)

  Male

1†

 Director education

  Post-graduate training or more

1.04 (0.55, 1.95)

  College or less

1†

 Director sources of information

2.35 (1.39, 3.97)**

 Director support of preventive services

1.06 (0.78, 1.45)

Control variables

  Patient characteristics

  Percent African-American patients

0.99 (0.97, 1.00)

  Percent Hispanic / Latino patients

1.01 (0.99, 1.02)

  Percent female patients

1.01 (0.99, 1.03)

  Percent persons who inject drugs

0.99 (0.98, 1.00)

  Program characteristics

  CARF accreditation

   Yes

0.63 (0.31, 1.24)

   No

1†

  Ownership

   Public

3.05 (1.20, 7.72)*

   Private for-profit

1.32 (0.62, 2.80)

   Private not-for-profit

1†

  Method of treatment

   Both (Meth + Bup)

2.10 (0.98, 4.48)^

   Buprenorphine only (Bup)

0.14 (0.05, 0.33)***

   Methadone only (Meth)

1†

  Staff - patient ratio

1.70 (1.14, 2.54)*

  Prior authorization

1.00 (0.99, 1.01)

  Revenue from federal sources

   At least 1%

1.97 (0.98, 3.90)*

   None

1†

  Revenue from private insurance

   At least 1%

1.35 (0.70, 2.60)

   None

1†

  Year

   2005

4.74 (2.45, 9.13)***

   2011

1†